NORD comments on Reauthorization of the Prescription Drug User Fee Act
Published: Aug 21, 2020
Tagged in: User Fee Act, Advancing Rare Disease Research and Regulatory Science
For decades, NORD has pursued federal and state policies that will change the lives of Americans impacted by rare diseases for the better. NORD’s work can be viewed below. This page is updated daily to provide timely information. Please contact us if you have questions or need additional information.
NORD comments on Reauthorization of the Prescription Drug User Fee Act
Published: Aug 21, 2020
Tagged in: User Fee Act, Advancing Rare Disease Research and Regulatory Science
NORD submits comments to FDA on Request for Information on Rare Disease Clinical Trial Networks
Published: Jul 31, 2020
Tagged in: Advancing Rare Disease Research and Regulatory Science, Rare Disease Clinical Trials, Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP)
NORD submits comments on FDA Draft Guidance on Interpreting Sameness for Gene Therapy Products Under the Orphan Drug Regulations
Published: Jul 28, 2020
Tagged in: Gene Therapies, Advancing Rare Disease Research and Regulatory Science, Orphan Drug Act
NORD comments given at the Food and Drug Administration’s (FDA) Rare Disease Day public meeting
Published: Feb 24, 2020
Tagged in: Access to Innovative Medicines and Therapies, Advancing Rare Disease Research and Regulatory Science, Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP)
NORD sign-on letter from over 40 rare disease patient organizations asking Congress to protect immigrants with rare diseases after having participated in clinical trials
Published: Sep 24, 2019
Tagged in: Immigration, Advancing Rare Disease Research and Regulatory Science
Coalition statement expressing concern about the Administration’s recent action on medical deferred action
Published: Sep 11, 2019
Tagged in: Immigration, Advancing Rare Disease Research and Regulatory Science